Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11060254 | PMC |
| http://dx.doi.org/10.1097/MS9.0000000000002029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). II. Drugs in more advanced clinical development.
Epilepsia
October 2024
Department of Pharmacy, Center for Epilepsy Drug Discovery, School of Pharmacy, University of Washington, Seattle, Washington, USA.
Article Synopsis
- The 17th Eilat Conference on New Antiepileptic Drugs and Devices was held in Madrid from May 5-8, 2024, focusing on investigational drugs for epilepsy.
- Presentations included advanced clinical compounds with available antiseizure activity data, such as azetukalner, bexicaserin, radiprodil, soticlestat, and STK-001.
- The diversity in these compounds reflects various approaches to developing new treatments for seizures and epilepsy, with some already showing efficacy in clinical trials.
XEN1101, a novel potassium channel opener: hope or hype for adults with focal seizure.
Ann Med Surg (Lond)
May 2024
Ahfad University for Women, Omdurman, Sudan.
A profile of azetukalner for the treatment of epilepsy: from pharmacology to potential for therapy.
Expert Rev Clin Pharmacol
May 2024
Innovation, Research and Teaching Service (SABES-ASDAA), Teaching Hospital of the Paracelsus Medical Private University (PMU), Bolzano, Italy.
Introduction: Epilepsies are a group of heterogeneous brain disorder, and antiseizure medications (ASMs) are the mainstay of treatment. Despite the availability of more than 30 drugs, at least one third of individuals with epilepsy are drug-resistant. This emphasizes the need for novel compounds that combine efficacy with improved tolerability.
View Article and Find Full Text PDFCurrent state of the epilepsy drug and device pipeline.
Epilepsia
April 2024
NYU Grossman School of Medicine and NYU Langone Health, New York, New York, USA.
Article Synopsis
- * Ongoing challenges include creating effective and well-tolerated therapies for diverse epilepsies, along with the need for precision treatments for rare cases and enhanced seizure-monitoring technologies.
- * Development efforts focus on targeting genetic factors, ion channels, neurotransmitters, and exploring new treatments using stem cells and electrical neuromodulation techniques.
Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial.
JAMA Neurol
November 2023
Xenon Pharmaceuticals, Vancouver, British Columbia, Canada.
Importance: Many patients with focal epilepsy experience seizures despite treatment with currently available antiseizure medications (ASMs) and may benefit from novel therapeutics.
Objective: To evaluate the efficacy and safety of XEN1101, a novel small-molecule selective Kv7.2/Kv7.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!